Information needed about our 145 affiliated companies worldwide?

Prof.* Dr Dr Andreas Barner is Chairman of the Board of Managing Director. He is also Head of Corporate Board Division Pharma Research, Development and Medicine.

_{* Republic of Austria}

Whatever the degree of financial control, Boehringer Ingelheim's subsidiary companies are selfmanaging and have a large degree of operational independence. They rely on Boehringer Ingelheim GmbH for strategic services and investment and make a profit contribution to the Corporation.

The Boehringer Ingelheim Corporation has voting shares, not equity shares which can be traded or listed on any stock market or index. The Corporation has been a family-owned business for nearly 125 years.

Would you like to receive printed copies of it, please contact us.

Value through Innovation has guided and will continue to guide our way of working together. It helps us build on our strength and make the most of our distinctive character, enabling us individually and collectively to achieve great success. Our vision is the driver of our culture and allows us to meet our future challenges ahead. Our vision is derived from our Leitbild which is the heart of who we are and why we exist as Boehringer Ingelheim. "Value through Innovation" means for us analysing and anticipating the value that customers will put on our products and services and then seeking to increase it by finding new and better ways of achieving the customer's goal.

Find out more about the company's history.

This situation persisted until well after the World War II, when the two companies agreed to rename themselves Boehringer Ingelheim and Boehringer Mannheim in order to reduce the confusion somewhat.

On employment, Boehringer Ingelheim has received numerous awards. Our affiliated companies participate successfully in surveys evaluating Boehringer Ingelheim as employer.

Average capacity of employees by region:
Europe:      21,016
Americas:  13,491
AAA:             7,717

Find out more about our Biopharmaceuticals business.

Modern biotechnology is key for the discovery, development and production of innovative drugs to treat unmet medical needs. The importance of biotechnology has grown significantly since 1990, when less than 1% of all drugs were biopharmaceuticals, whereas today biopharmaceuticals represent 8%. The biopharmaceutical market overall is forecasted to grow at nearly 7% through to 2015, with monoclonal antibodies showing higher growth of 9%. Boehringer Ingelheim has established its reputation with a successful market introduction of 15 DNA-derived biopharmaceuticals produced for captive use and third party business. Four of these products are among the top 20 of the worldwide selling list. We continuously move ahead advancing with the benefit of our own research, through collaboration with research-oriented companies and our commercial partners, and working with leading academic networks.

Boehringer Ingelheim offers the entire production chain at its biopharmaceutical manufacturing facilities in Vienna (Austria) and Biberach (Germany).

At the Vienna site we produce therapeutics derived from bacterial and yeast fermentation and at the Biberach site we produce biopharmaceuticals derived from mammalian cell cultures.

All our production plants operate under cGMP and are approved by European, US, Canadian and Japanese authorities.

All Pharmaceuticals Production's manufacturing facilities operate in strict compliance with current good manufacturing practice (cGMP) and are inspected and certified by regulatory agencies across the globe (FDA, EMEA, MHRA, ANVISA, ASEAN). In addition, our facilities are subject to regular inspections from Boehringer Ingelheim corporate auditors, ensuring a continuous improvement and a high level of cGMP awareness.

It has five chemicals production sites in France, Germany, Spain and the USA that form an effective worldwide network. These sites offer state-of-the-art chemical development facilities, experienced chemists, analytical expertise and highly flexible, multi-purpose production plants with the capacity to upscale extremely complex chemicals from one-kilo to multi-ton levels.

Animal Health is one of our two business areas. Although small relative to our Human Pharmaceuticals business, it is growing significantly above market and showing increasingly improved profitability. Boehringer Ingelheim's Animal Health business holds an international market share of 5.9%, putting it in the 6th position in the market. Our research-driven expertise and human pharmaceuticals excellence ensures to contribute to a safe and nutritious food supply and helps companion animals to live a longer and healthier life. We plan to focus more on preventative solutions and aim to become world market leader with our swine biologicals.

Partnering is essential part of our strategy to discover and market true innovations. Our strong pipeline complemented by our partnering activities is the basis for our dynamic growth above the market.

Contract and Alliance Management
Global Team located in Germany, Japan and US responsible to negotiate and manage local and international partnering agreements. Rapid and transparent deal making processes are supported by dedicated professionals, empowered by senior management. Strong focus on business and contract-related matters ensures high level of commitment and experience concerning drafting, negotiation and management of agreements.

Our chapter Licensing & Partnering informs about

• what you get
• our areas of interest
• examples of our partnerships and
• partnering events.

Boehringer Ingelheim has launched its corporate venture capital fund, the Boehringer Ingelheim Venture Fund (BIVF) on 30 March 2010. The BIVF aims to invest in Biotech and Start-up companies that provide ground-breaking therapeutic approaches and technologies to help drive innovation in medical science. These may include - but are not limited to - new therapeutic concepts including stem cells and RNA silencing as well as new generation vaccines, new generation protein or antibody technologies, new molecular targets and/or first-in-class lead compounds. Disease-related biomarkers would be an additional area of focus. Investment opportunities will be sought on a worldwide basis. For further information about the BIVF, please visit our related website.

In order to substantially extend access to the active ingredient Nevirapine, Boehringer Ingelheim in May 2007 decided to not enforce its patents and offers interested manufactures listed on the WHO prequalification programme non-assert declarations enabling them at no additional costs to supply Nevirapine-containing medicines for eligible countries.

These eligible countries are defined as all low income countries according to the World Bank classification of economies, all countries classified as Least Developed Country (LDC) according to the United Nations Development Programme and all African states which are not classified as low income of LDC.

The policy has been positively received and has encouraged the emergence of quality generic products with the active ingredient Nevirapine in developing countries. It applies to Viramune® IR (immediate release) and will also include Viramune® XR (extended release) once launched.

The protease inhibitor Aptivus® (Tipranavir) also falls under this policy.

The company offers a tiered preferential price. Viramune® can be supplied at:

• Not-for-profit price for all low income countries according to the World Bank classification of economies, all countries classified as Least Developed Country (LDC) according to the United Nations Development Programme and all African states which are not classified as low income of LDC.

• Reduced price for all middle income countries not benefiting from the not-for-profit price.

The preferential prices apply to the supply to the public sector in the countries.

Since its inception, the Viramune® Donation Programme has contributed to preserving the health of babies born to HIV+ mothers throughout the developing world. In the intervening decade, medicine sufficient for the management of more than 2 million mother-child pairs was donated to pmtct projects throughout the world.
Over the ten years since the start of the Viramune® Donation Programme, there have been new developments and new insights into the therapies that can be offered to reduce mtct of HIV-1 even further. Single dose Viramune® (with its active ingredient Nevirapine) as employed in the Viramune® Donation Programme is no longer considered as an appropriate approach for this purpose.
More comprehensive regimens have been developed and have been included in the latest guidelines on pmtct launched by WHO in July of 2010 at the World Aids Conference in Vienna.

In the light of these modified guidelines, Boehringer Ingelheim will pursue its commitment in a modified form. Two aspects will be involved:

First, where countries experience difficulties in the transition to the new guidelines, the company will provide interim assistance, on request, to the sites we have supported in the past, with supplies of Viramune® (tablets and 20 ml suspension) until the end of 2013.

Second, the 20 ml bottle of Viramune® oral suspension for children, previously donated for pmtct as part of the VDP, will become obsolete; the larger 240 ml pack of Viramune® oral suspension will now be offered for use in pmtct programmes at a not-for-profit price.

The decision to transform the current approach to pmtct will not cause problems of supply. Other products containing the active ingredient Nevirapine, both tablets and oral suspension, are now widely available in the developing world, from a number of appropriately qualified generic manufacturers. Boehringer Ingelheim has made a non-assert declaration to generic manufacturers pre-qualified by the WHO, to manufacture products containing the active ingredient Nevirapine for the developing world.

Boehringer Ingelheim regards capacity building and human resources development as a crucial objective in any health care development policy in emerging economies. This is the genuine task of committed Governments, supported by the private sector and civil society as well as bilateral or international assistance programmes. Boehringer Ingelheim contributes to this endeavour, for example with active involvement in capacity building, health education and training programmes, improving health care infrastructure and special efforts such as strengthening of supply chain management systems.